Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st, 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.
As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Consequently, Ipsen Group’s securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
Ipsen receives its second Shingo Prize for operational excellence
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade